Newsroom

IsoRay Names Jonathan Hunt New Chief Financial Officer

RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...

read more

IsoRay Announces First Quarter Fiscal 2019 Financial Results

Year Over Year First Quarter Revenues Increased 29% Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter   RICHLAND, WASHINGTON - November 8, 2018 -- IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed...

read more

IsoRay, Inc. Closes $8,250,000 Registered Direct Offering

RICHLAND, Wash., July 12, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...

read more

IsoRay Announces $8.25 Million Registered Direct Offering

RICHLAND, Wash., July 09, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...

read more

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
(302) 539-3747